FDA Guidance Slows the Decent: (CTIC) Tech24 Cell Therapeutics Inc. (NASDAQ: CTIC) announced that the FDA has provided the guidance for design of Pixantrone Pivotal Trial. The company officials had earlier met with the FDA officials in this regard. At the meeting, the FDA requested additional ... |
Thursday, March 10, 2011
FDA Guidance Slows the Decent: (CTIC) - Tech24
firearms-somewhat.blogspot.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment